Skip to main
ACET

ACET Stock Forecast & Price Target

ACET Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Adicet Bio is a clinical-stage biotechnology company with a positive financial outlook due to its promising pipeline of allogeneic gamma delta T cell therapies, including prulacabtagene leucel and ADI-212, which have shown strong efficacy in treating autoimmune diseases and cancer. Despite competition in the autoimmune landscape, prulacabtagene leucel stands out for its efficacy, safety profile, and allogeneic nature. With a net loss of $21.4MM in 2Q26 and operational runway until 2H27, Adicet remains a buy with a lowered 12-month price target of $27 per share due to increased long-term operating expenses and a higher discount rate. Risks include potential setbacks in clinical development and failure to obtain regulatory approvals, but the potential market value of $306M offers significant upside potential.

Bears say

Adicet Bio is facing numerous risks, including potential delays in clinical trial initiation and the failure of their clinical studies for Lupus/SSc. These setbacks, combined with the possibility of new competitors arising, have raised concerns about the company's future success. Additionally, with no current source of cash flow, Adicet Bio may face the need to raise money in the markets, which could further impact its profitability in the short term.

ACET has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Adicet Bio, Inc. and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Adicet Bio, Inc. (ACET) Forecast

Analysts have given ACET a Strong Buy based on their latest research and market trends.

According to 4 analysts, ACET has a Strong Buy consensus rating as of Aug 8, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $38.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $38.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Adicet Bio, Inc. (ACET)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.